WO1998027227B1 - Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux - Google Patents

Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux

Info

Publication number
WO1998027227B1
WO1998027227B1 PCT/IB1997/001648 IB9701648W WO9827227B1 WO 1998027227 B1 WO1998027227 B1 WO 1998027227B1 IB 9701648 W IB9701648 W IB 9701648W WO 9827227 B1 WO9827227 B1 WO 9827227B1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
disease
diagnosed
allele
phenotyping
Prior art date
Application number
PCT/IB1997/001648
Other languages
English (en)
Other versions
WO1998027227A2 (fr
WO1998027227A3 (fr
Filing date
Publication date
Priority claimed from US08/766,975 external-priority patent/US6022683A/en
Application filed filed Critical
Priority to AU56757/98A priority Critical patent/AU745073B2/en
Priority to CA002275504A priority patent/CA2275504C/fr
Priority to DE69729473T priority patent/DE69729473T2/de
Priority to EP97953011A priority patent/EP0946753B1/fr
Priority to JP52750798A priority patent/JP2001524809A/ja
Publication of WO1998027227A2 publication Critical patent/WO1998027227A2/fr
Publication of WO1998027227A3 publication Critical patent/WO1998027227A3/fr
Publication of WO1998027227B1 publication Critical patent/WO1998027227B1/fr

Links

Abstract

La présente invention se rapporte à un procédé permettant de diagnostiquer une maladie neurologique et d'établir la thérapie adaptée à un patient chez qui l'on a diagnostiqué une telle maladie. La présente invention se rapporte également à un procédé d'identification de sujets humains sélectionnés pour subir des essais cliniques de médicaments dont on vérifie l'aptitude à traiter des maladies neurologiques.
PCT/IB1997/001648 1996-12-16 1997-12-16 Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux WO1998027227A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU56757/98A AU745073B2 (en) 1996-12-16 1997-12-16 Pharmacogenetic methods for use in the treatment of nervous system diseases
CA002275504A CA2275504C (fr) 1996-12-16 1997-12-16 Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux
DE69729473T DE69729473T2 (de) 1996-12-16 1997-12-16 Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
EP97953011A EP0946753B1 (fr) 1996-12-16 1997-12-16 Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux
JP52750798A JP2001524809A (ja) 1996-12-16 1997-12-16 神経系疾患の治療に使用するための遺伝薬理学的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/766,975 1996-12-16
US08/766,975 US6022683A (en) 1996-12-16 1996-12-16 Methods for assessing the prognosis of a patient with a neurodegenerative disease

Publications (3)

Publication Number Publication Date
WO1998027227A2 WO1998027227A2 (fr) 1998-06-25
WO1998027227A3 WO1998027227A3 (fr) 1998-08-27
WO1998027227B1 true WO1998027227B1 (fr) 1998-10-15

Family

ID=25078098

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1997/001648 WO1998027227A2 (fr) 1996-12-16 1997-12-16 Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux
PCT/IB1997/001641 WO1998027226A2 (fr) 1996-12-16 1997-12-16 Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/001641 WO1998027226A2 (fr) 1996-12-16 1997-12-16 Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique

Country Status (8)

Country Link
US (2) US6022683A (fr)
EP (2) EP0948647B1 (fr)
JP (4) JP2001524809A (fr)
AT (1) ATE269978T1 (fr)
AU (2) AU745073B2 (fr)
CA (2) CA2275504C (fr)
DE (2) DE69729654T2 (fr)
WO (2) WO1998027227A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US6441149B1 (en) 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6218117B1 (en) 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
CA2330829C (fr) * 1998-06-16 2011-08-02 Nova Molecular, Inc. Procedes relatifs au traitement d'une maladie neurologique par determination du genotype de butyrylcholinesterase (bche)
AU773765B2 (en) 1998-10-01 2004-06-03 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele
WO2000070340A2 (fr) * 1999-05-14 2000-11-23 Karolinska Innovations Ab Materiaux et procedes se rapportant au diagnostic de maladie
EP1208421A4 (fr) * 1999-06-25 2004-10-20 Genaissance Pharmaceuticals Obtention et utilisation de donnees sur les haplotypes
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001069261A2 (fr) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
AU2002363329A1 (en) * 2001-11-06 2003-05-19 Elizabeth Gray Pharmacogenomics-based system for clinical applications
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030224446A1 (en) * 2001-12-20 2003-12-04 Harry G. Jean Method of predicting cytokine response to tissue injury
US20040267458A1 (en) * 2001-12-21 2004-12-30 Judson Richard S. Methods for obtaining and using haplotype data
AU2003216186A1 (en) * 2002-02-14 2003-09-04 Medavante, Inc. System and method for facilitating candidate and subject participation in clinical trial studies
US7432355B2 (en) * 2002-08-09 2008-10-07 The J. David Gladstone Institutes Apolipoprotein E stable folding intermediate and methods of use thereof
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
WO2004111652A1 (fr) * 2003-06-19 2004-12-23 Applied Research Systems Ars Holding N.V. Utilisation d'agents modulateurs de la conversion de prions
US20050038692A1 (en) * 2003-08-14 2005-02-17 Kane John Michael System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies
ZA200605829B (en) * 2004-01-16 2007-11-28 Disease Man Services Plc Disease Management System
US8466144B2 (en) 2004-07-16 2013-06-18 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20070135376A1 (en) * 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
EP2508621B1 (fr) * 2005-11-29 2014-11-05 Children's Hospital Medical Center Optimisation et personnalisation de selection et de sosage de medicaments
HUE040002T2 (hu) * 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
US20080126118A1 (en) * 2006-11-24 2008-05-29 General Electric Company, A New York Corporation Systems, methods and apparatus for a network application framework system
TWI362012B (en) * 2007-07-23 2012-04-11 System of providing hygienic education information and method thereof
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
US20090198504A1 (en) * 2008-02-05 2009-08-06 Medavante, Inc. Rater resource allocation systems and methods
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
WO2010003114A1 (fr) * 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglycéride d'acétoacétate et dérivés pour le traitement de troubles neurologiques
EP2387405A2 (fr) 2009-01-13 2011-11-23 ProteoSys AG Pirenzépine en tant qu'agent utilisé dans le traitement du cancer
EP2360280A1 (fr) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Marqueur génétique pour le diagnostic de la démence doté de corps de Lewy
US20120078521A1 (en) * 2010-09-27 2012-03-29 General Electric Company Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
RU2467680C1 (ru) * 2011-10-04 2012-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования эффективности лечения больных ишемическим инсультом
US10665328B2 (en) 2014-06-30 2020-05-26 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests
US10658073B2 (en) 2014-08-15 2020-05-19 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics
EP3628315A1 (fr) 2018-09-28 2020-04-01 Université de Caen Normandie Combinaison d'inhibiteur d'acétylcholinestérase et d'agoniste de récepteur de 5-ht4 comme agent neuroprotecteur dans le traitement de maladies neurodégénératives
WO2020091375A2 (fr) * 2018-10-29 2020-05-07 고려대학교 산학협력단 Procédé et système de recommandation d'antidépresseur

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
CA2111503A1 (fr) * 1993-12-15 1995-06-16 Mcgill University Polymorphisme de l'apolipoproteine e et maladie d'alzheimer
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease

Similar Documents

Publication Publication Date Title
WO1998027227B1 (fr) Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux
Parker Jr et al. Cytochrome oxidase deficiency in Alzheimer's disease
Prasher et al. Molecular mapping of Alzheimer‐type dementia in Down's syndrome
WO1998027227A3 (fr) Procedes pharmacogenetiques destines au traitement de maladies du systeme nerveux
WO1998027226B1 (fr) Procede d'etablissement d'un pronostic pour un patient atteint d'une maladie neurologique
EP0764914A3 (fr) Procédé pour l'allocation de lits dans une station intensive de pédiatrie et pour l'évaluation de la qualité des soins
CA2188933A1 (fr) Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer
EP1521083A3 (fr) Procédé pour le diagnostic et la caractérisation de l'attaque cérébrale
Chu et al. Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease
EP1361229A3 (fr) Utilisation de la Tyrosine Kinase (PYK2) pour la production d'anticorps
EP2397492A3 (fr) Mutants d'angiogenine dans la sclérose amyotrophique laterale
AU2002237296A1 (en) Conformationally abnormal forms of tau proteins and specific antibodies thereto
WO2002089657A3 (fr) Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
Zhang et al. Evidence for the early onset of gingival inflammation following short‐term plaque accumulation
EP2644588A3 (fr) Biomarqueurs pour le diagnostic de la sclérose en plaques et procédés associés
AU8969098A (en) Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
EP1434053A4 (fr) Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire
Bouhouche et al. Autosomal recessive mutilating sensory neuropathy with spastic paraplegia maps to chromosome 5p15. 31–14.1
Reinhardt et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease
IL123834A0 (en) Diagnostic method and kit for determining rh blood group genotype
CA2251744A1 (fr) Procedes pour identifier la predisposition a l'osteoarthrose par un genotype recepteur de la vitamine d
AU6823600A (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
AU1153300A (en) Methods of diagnosing or prognosing alzheimer's disease
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
JP2007500005A5 (fr)